Abstract: Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.
Type:
Grant
Filed:
October 4, 2017
Date of Patent:
July 6, 2021
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE BORDEAUX, INSTITUT BERGONIÉ
Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
February 11, 2020
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE BORDEAUX, UNIVERSITÉ DE RENNES, ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP), UNIVERSITÉ DES ANTILLES ET DE LA GUYANE, INSTITUT BERGONIÉ, UNIVERSITY OF NOTTINGHAM
Inventors:
Patrick Legembre, Pierre Vacher, Doriane Sanseau, Aubin Penna, Robin Flynn
Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of soft tissue sarcoma cancer phenotypes and soft tissue sarcoma cancer-associated diseases. Also described herein are methods that can be used to identify modulators of soft tissue sarcoma cancer.
© 2026 Justia
